Magnesium Oxide Softgel Fill Composition for Faster Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing softgel capsules filled with magnesium oxide exhibit low solubility and bioavailability due to poor interaction with the shell material, leading to inadequate dissolution rates that fail to meet the USP dissolution test requirements.
Innovation Solution
Formulation of softgel capsules containing magnesium oxide with a composition of 55-70% edible oil, 2-8% polysorbate 80, 0.5-2% hydrophobic silica, and 0.2-4% chelating agent, such as EDTA salt and weak acids, to enhance solubility and stability, preventing hydration reactions and improving dissolution performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If magnesium oxide is encapsulated in softgel capsules, then consumer preference and manufacturing speed are improved, but dissolution rate decreases due to reaction with shell water forming less soluble Mg(OH)2
Solution Approach 1:
The patent applies preliminary action by incorporating hydrophobic silica and chelating agents into the fill composition before encapsulation. These additives preemptively prevent the reaction between magnesium oxide and shell water, blocking the formation of magnesium hydroxide before it can occur during storage. This advance preparation ensures the magnesium oxide remains in its original form and maintains high dissolution rates when the capsule is consumed.
Solution Approach 2:
The patent uses hydrophobic silica as an intermediary substance that physically separates magnesium oxide from shell water. The hydrophobic silica creates a protective barrier that prevents direct contact between water and magnesium oxide, thereby preventing the unwanted chemical reaction. The chelating agents also act as intermediaries by binding to magnesium ions and preventing their precipitation as hydroxide.
2Ease of manufacture
If high temperature and humidity are used during manufacturing, then encapsulation efficiency is improved, but cross-linking of capsule shell increases which slows dissolution rate
Solution Approach 1:
The patent applies the taking out principle by removing the problematic interaction between shell water and magnesium oxide through the use of hydrophobic silica. This additive extracts or removes the harmful effect of water contact by creating a hydrophobic barrier, allowing high temperature and humidity processing to proceed without causing excessive cross-linking that would impair dissolution.
3Quantity of substance
If magnesium oxide is used instead of organic magnesium salts, then elemental magnesium loading is improved, but water solubility decreases leading to poor bioavailability
Solution Approach 1:
The patent applies composite materials by creating a multi-component fill composition that combines magnesium oxide with hydrophobic silica and chelating agents. This composite formulation leverages the high elemental magnesium content of MgO while the added components work together to enhance solubility and prevent precipitation, achieving both high loading and good bioavailability simultaneously.
Solution Approach 2:
The patent uses parameter changes by modifying the chemical environment within the capsule through the addition of chelating agents. These agents change the solubility parameters of the system by forming soluble complexes with magnesium ions, thereby increasing water solubility and bioavailability while maintaining the high elemental magnesium loading provided by magnesium oxide.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves dissolution rates exceeding the USP requirements of at least 75% for magnesium oxide, maintaining stability under various storage conditions, and providing a reliable magnesium supplement.
Implementation Method 1
2-8% polysorbate 80
Implementation Method 2
0.5-2% hydrophobic silica, preventing hydration reactions
Implementation Method 3
0.2-4% chelating agent, such as EDTA salt and weak acids, to enhance solubility and stability
Data Source
AI summary
Softgel capsules have a fill composition that administers a 200 to 500 mg dose of magnesium from magnesium oxide and an outer sofgel gelatin shell. The composition includes 55 to 70% w/w of an edible oil, 2 to 8% w/w polysorbate 80, 0.5 to 2% w/w hydrophobic silica, and 0.2 to 4% w/w of a chelating agent for binding to magnesium. The softgel capsules have a dissolution according to USP <711> of greater than NLT 75% (Q).